Sign in
IPSC Stock Price, Chart, Stats & News
Century Therapeutics, Inc.
Save
198.24M
Market cap
–
Current P/E
–
Forward P/E
IPSC chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 90.95% |
Operating margin | -13.78% |
Pretax margin | -8.84% |
Net margin | -8.78% |
Effective tax rate | 0.70% |
ROA | -4.28% |
ROE | -4.88% |
D/E | 0.27x |
Interest coverage ratio | – |
IPSC valuation
P/E | – |
P/S | 1.60x |
P/B | 1.10x |
P/CF | -1.68x |
P/FCF | -1.67x |
P/OCF | -1.68x |
PEG | -0.27x |
EV multiple | -99.62x |
About
Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogeneic, induced pluripotent stem cell (iPSC)-derived CAR-iNK cell therapy. This therapy is specifically designed to target CD19 in patients with B-cell lymphoma that has relapsed or proven refractory to previous treatments.
Similar securities
Based on sector and market capitalization
Report issue